Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

Cancers

Alberto Zambelli¹  Lorenzo Gerratana²  Fabio Puglisi²  Mattia Garutti²  Caterina Marchiò³  Francesco Perrone⁴  Michelino De Laurentiis⁵  Sabino De Placido⁶  Carmine De Angelis⁶  Vincenzo Adamo⁷  Lucia Del Mastro⁸  Chiara Molinelli⁸  Giulia Buzzatti⁸  Giampaolo Bianchini⁹  Giuseppe Viale^1,10  Andrea Botticelli^1,11  Valentina Guarneri^1,12  Gaia Griguolo^1,12  Alessandra Gennari^1,13  Antonio Frassoldati^1,14  Giuseppe Curigliano^1,15  Paolo Marchetti^1,16  Claudio Zamagni^1,17  Laura Biganzoli^1,18  Alessandra Fabi^1,19 

[1] Breast Cancer Section Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, 20089 Milan, Italy;CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy;Candiolo Cancer Institute, FPO IRCCS, 10060 Candiolo, Italy;Clinical Trials Unit, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione Pascale, 80144 Naples, Italy;Department of Breast and Thoracic Oncology, IRCCS INT Fondazione G. Pascale, 80144 Napoli, Italy;Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy;Department of Human Pathology, Papardo Hospital, University of Messina, 89121 Messina, Italy;Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16100 Genova, Italy;Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy;Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy;Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00100 Rome, Italy;Department of Surgery, Oncology and Gastroenterology, University of Padova, 35100 Padova, Italy;Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy;Department of Traslational Medicine and for Romagna, Clinical Oncology, S Anna University Hospital, Università degli Studi di Ferrara, 44121 Ferrara, Italy;Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20100 Milan, Italy;IRCCS Istituto Dermopatico dell’Immacolata (IDI-IRCCS), 00167 Rome, Italy;Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, 40100 Bologna, Italy;Ospedale Santo Stefano, Prato Sandro Pitigliani Medical Oncology Division, Hospital of Prato, 59100 Prato, Italy;Precision Medicine in Breast Cancer Unit, Department of Woman and Child Health and Public Health, IRCCS, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy;

关键词: breast cancer;    hormone receptors;    adjuvant;    endocrine therapy;    chemotherapy;    risk of relapse;   

DOI  :  10.3390/cancers14081898

来源: DOAJ

【 摘 要 】

Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.

【 授权许可】

Unknown